We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Clinical Dentistry

Journal Scan / Research · October 06, 2022

Optimal Threshold and Prognostic Utility of Pre-Treatment Hemoglobin Level as a Biomarker for Survival in Patients With Head and Neck Cancer Receiving Chemoradiation

Oral Oncology

 

Additional Info

Oral Oncology
Defining the optimal threshold and prognostic utility of pre-treatment hemoglobin level as a biomarker for survival outcomes in head and neck cancer patients receiving chemoradiation
Oral Oncol 2022 Oct 01;133(2022)106054, SJ Ma, H Yu, M Khan, B Yu, S Santhosh, U Chatterjee, J Gill, A Iovoli, M Farrugia, K Wooten, V Gupta, R McSpadden, MA Kuriakose, MR Markiewicz, A Al-Afif, WL Hicks, ME Platek, M Seshadri, AD Ray, E Repasky, AK Singh

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading